BAM Logo

Urine Drugs of Abuse

[Urine Drugs of Abuse ]

EPTIS factsheet 187906 | Last revision 2024-05-22 | URL: https://www.eptis.bam.de/pts187906 https://www.eptis.bam.de/pts187906

PT provider
PT provider Weqas Weqas
Based in United Kingdom
Remarks The initial analysis is a screening test for commonly abused drug groups, e.g opiates, benzodiazepines, barbiturates, cannabinoids, amphetamines and cocaine, drugs used in the treatment of opiate addiction (methadone and buprenorphine) and novel psychoactive substances. Initial screens are based on immunoassays (laboratory and POCT) with a further confirmatory analysis in a laboratory using GC-MS. The use of Gravimetric ‘weighed in’ values as a performance target in EQA data provides a stable, independent target that is not influenced by the overall or method mean. The linear panel of samples are distributed on a number of occasions facilitating the assessment of linearity, within and between batch precision and traceability, providing laboratories with ongoing evidence for their compliance to ISO 15189. Eighteen samples are distributed annually. Key Features: - Samples include different panels of drug / metabolites. Linear samples cover analytical and clinically relevant ranges including at or near lower limit of detection for qualitative methods. - Suitable for qualitative and quantitative results. - Suitable for both laboratory and POCT devices. - Traceable, “gravimetric” concentration of metabolite and 1° drug. - Programme assesses both laboratory and method performance, including, linearity (recovery to gravimetric), specificity, bias, within and between batch imprecision. For more information: https://www.weqas.com/participantzone/subscription-charges/ or contact@weqas.com
Product groups Health care / medical devices
Testing fields Medical analysis
Technical details
Test item Tested property Testing method
Fresh filtered urine with 1° and 2° metabolites added Amphetamine Routine testing methods (recommended)
Amphetamines Group Screen Routine testing methods (recommended)
Benzodiazepine Routine testing methods (recommended)
Barbiturate Routine testing methods (recommended)
Buprenorphine Routine testing methods (recommended)
Cocaine Routine testing methods (recommended)
Cannabis Routine testing methods (recommended)
EDDP Routine testing methods (recommended)
Heroin Routine testing methods (recommended)
Ketamine Routine testing methods (recommended)
MDMA Routine testing methods (recommended)
Methadone Routine testing methods (recommended)
Methamphetamine (mAMP) Routine testing methods (recommended)
Opiates (Morphine) Routine testing methods (recommended)
Phencyclidine (PCP) Routine testing methods (recommended)
Tricyclic Antidepressants (TCA) Routine testing methods (recommended)
Aims of the PT scheme
Target group of participants Urine testing for both prescribed and illicit drugs is increasingly used in both Laboratory and Point of Care settings.
Linked to specific legislation / standards UKAS ISO/IEC 17043
Additional, subsidiary aims validation of testing methods
Number of participants
Accredited or otherwise reviewed by a 3rd party

Accredited by UKAS on the basis of ISO/IEC 17043

Operation is commissioned / requested by
Fees and frequency
Participation fee https://www.weqas.com/participantzone/subscription-charges/
Regularly operated Yes (Frequency: Bimonthly. Samples: 3 x 3.0mL. )
Year of first operation 2016
Contact details of the PT provider
Provider Contact person
Unit 6, Parc Ty Glas
CF14 5DU Cardiff
United Kingdom

Phone: 44 (0) 2920 314750
Web: http://www.weqas.com http://www.weqas.com
Laura Lloyd-Lewis
Phone: 44 (0) 29218 32884
Email: laura.lloyd-lewis@wales.nhs.uk laura.lloyd-lewis@wales.nhs.uk
If you find any mistakes please contact the responsible EPTIS coordinator in United Kingdom, Mr Savvas Xystouris. Mr Savvas Xystouris.
Any questions or problems? Please contact us at eptis@bam.de.
Application version: 1.23-SNAPSHOT.20230502124635-7925ae379a631fc1ececff45d2921c8db38877d5